Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246280 · ClinicalTrials.gov registry record · Phase 3
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
A Phase 3 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT05246280: Clinical Trial Phase 3 study, sponsored by Navidea Biopharmaceuticals.
NCT05246280 is a Phase 3 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 169 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05246280, a Phase 3 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
Primary Outcome
Specificity of the change in TUVglobal with bucketing from baseline to 5 weeks after a change in anti-TNFα therapy (ΔTUVglobal\[5w\] with bucketing) with respect to ACR50 at week 24 after the change in therapy.
Interventions
- DRUG TC99m-tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 3 |
Why NCT05246280 stopped before completion
NCT05246280 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which TC99m-tilmanocept is the first listed.
NCT05246280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05246280 about?
NCT05246280 is a clinical study titled "Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA". This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
What is the current status of trial NCT05246280?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2022-03-02. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT05246280?
The interventions under investigation include: TC99m-tilmanocept (DRUG).
Who is sponsoring clinical trial NCT05246280?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05246280's enrollment target sits among peer trials
169 1459th of 2000 higher than 542 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI